Table 4. 18F-FDG-PET for predicting outcome after liver transplantation for HCC.
| Authors | n | n (PET−/PET+) | Overall outcome (PET−/PET+) | Outcome beyond standard criteria (PET−/PET+) |
| Yang et al.70 | 38 | 25/13 | Overall 2y RFS: 85.1%/46.1% | RR beyond Milan: 60%/57% |
| Lee et al.71 | 59 | 38/21 | Overall 2y RFS: 97%/42% | RR beyond Milan: 9%/67% |
| Kornberg et al.72 | 42 | 26/16 | Overall 3y RFS: 93%/35% | RR beyond Milan: 11.1%/53.8% |
| Kornberg et al.73 | 55 | 36/19 | Overall 3y RFS: 93.3%/46.9% | 3y RFS beyond Milan: 80%/44% |
| Kornberg et al.74 | 91 | 56/35 | Overall RR: 3.6%/54.3% | 5y RFS beyond Milan: 81%/21% 5y RFS beyond UCSF: 85.7%/19.2% |
| Lee et al.75 | 191 | 136/55 | 3y RFS: 86.8%/57.1% | – |
| Lee et al.76 | 280 | 190/90 | 5y RFS within Milan: 92.3%/76.3% 5y RFS within UCSF: 91.9%/81.8% |
5y RFS beyond Milan: 73.3%/37.5% 5y RFS beyond UCSF: 72.8%/30.7% |
| Lee et al.77 | 280 |
NCCK–In/NCCK-Out 164/116 |
NCCK–In/NCCK-Out 5y RFS (clin. staging): 80.7%/45.1% 5y RFS (path. staging): 84%/44.4% 5y OS (clin. staging): 83.6%/59.8% 5y OS (path. staging): 85.2%/60.2% |
NCCK–In/NCCK Out + Milan In/beyond NCCK and Milan 5y RFS (clin. staging): 80.7%/75.5%/30.8% 5y RFS (path. staging): 84%/81%/30.8% 5y OS (clin. staging): 83.6%/73.5%/53.9% 5y OS (path. staging): 85.2%/73.8%/57.6% |
| Hsu et al.78 | 147 | 117/30 | Overall 5y RFS: 84.8%/68.3% |
Risk stratification based on PET and UCSF (low-risk/intermediate risk/high risk) 5y RFS (clin. staging): 85.5%/83.9%/29.6% 5y RFS (path. staging): 94.0%/75.8%/29.6% |
| Hong et al.79 | 123 | 87/36 | Overall 5y RFS: 93.4%/49.1% |
Risk stratification based on PET and AFP level (low risk/intermediate risk/high risk) Overall 5y RFS: 93.6%/77.7%/8.3% 5y RFS within Milan: 92.6%/73.9%/16.7% 5y RFS beyond Milan: 100%/100%/0% |
| Takade et al.80 | 182 | 139/43 | Overall RR: 12%/28% |
Risk stratification based on Milan, AFP and PET (Milan In or Milan Out + AFP <115ng/ml + PET−/Others) 5y OS: 75%/44% |
Abbreviations: AFP, alpha-fetoprotein; NCCK, National Cancer Center Korea; OS, overall survival; PET, positron emission tomography; RFS, recurrence-free survival; RR, recurrence rate; UCSF, University of California San Francisco.